DiaMedica Inc.
TSX VENTURE : DMA

DiaMedica Inc.

August 20, 2013 08:32 ET

DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study

MINNEAPOLIS, MINNESOTA--(Marketwired - Aug. 20, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today announced that the final Type 2 diabetic patient has been enrolled in the single ascending dose (SAD) portion of the DM199 Phase I/II clinical study. The randomized, placebo-controlled, double-blinded study is evaluating three dose levels in each Type 2 diabetic patient.

"Completion of the enrollment of Type 2 Diabetic patients into the SAD portion of the Phase I/II clinical study is an important milestone in our DM199 development pathway," said Rick Pauls, Chairman and CEO at DiaMedica. "We are looking forward to the top line results from this study which will be available in Q3 2013."

The primary objective of the SAD portion of the ongoing Phase I/II clinical study is to evaluate acute safety, tolerability and pharmacokinetic properties for the first time in Type 2 diabetic patients, as well as the effect of DM199 on improving glucose control.

About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. DiaMedica is also developing a novel monoclonal antibody, DM-204 for the treatment of Type 2 diabetes, which is in preclinical development.

The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information